WO2010110503A1 - 인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 IFN-α 융합 단백질 - Google Patents

인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 IFN-α 융합 단백질 Download PDF

Info

Publication number
WO2010110503A1
WO2010110503A1 PCT/KR2009/001575 KR2009001575W WO2010110503A1 WO 2010110503 A1 WO2010110503 A1 WO 2010110503A1 KR 2009001575 W KR2009001575 W KR 2009001575W WO 2010110503 A1 WO2010110503 A1 WO 2010110503A1
Authority
WO
WIPO (PCT)
Prior art keywords
ifn
ctp
fused protein
fused
interferon
Prior art date
Application number
PCT/KR2009/001575
Other languages
English (en)
French (fr)
Inventor
이찬규
양선영
강은주
류강
이현수
배용수
Original Assignee
주식회사 중외제약
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 중외제약 filed Critical 주식회사 중외제약
Priority to JP2012501917A priority Critical patent/JP5576928B2/ja
Priority to EP09842353.6A priority patent/EP2412730B1/en
Priority to US13/260,490 priority patent/US8623348B2/en
Priority to PCT/KR2009/001575 priority patent/WO2010110503A1/ko
Publication of WO2010110503A1 publication Critical patent/WO2010110503A1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 세포질 잔류성 세포막 투과 펩타이드(cytoplasmic transduction peptide. CTP)에 융합된 IFN(interferon)-α 를 포함하는 IFN-α 융합 단백질에 관한 것이다. 본 발명은 세포막 결합 및 간 이동 특성을 갖는 펩타이드인 CTP 를 사람 IFN-α에 유전적으로 융합하여 세포막 결합능력 및 항바이러스 활성이 향상되고, 세포핵으로의 이동은 억제되며, 간 이동 및 체류, 및 간 조직 침투가 우수한 효과를 가지는 융합 단백질이다. 이를 통해 저용량으로 각종 바이러스성 감염 등을 포함하는 간질환의 예방 또는 치료에 효과적인 단백질 의약품의 개발이 가능할 것이다.
PCT/KR2009/001575 2009-03-27 2009-03-27 인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 IFN-α 융합 단백질 WO2010110503A1 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2012501917A JP5576928B2 (ja) 2009-03-27 2009-03-27 インターフェロン−アルファ及び細胞質残留性細胞膜透過ペプチドを含むＩＦＮ−α融合タンパク質
EP09842353.6A EP2412730B1 (en) 2009-03-27 2009-03-27 Interferon-alpha (ifn-alpha ) fused protein having ifn-alpha and cytoplasmic transduction peptide (ctp)
US13/260,490 US8623348B2 (en) 2009-03-27 2009-03-27 Interferon-α (IFN-α) fused proteins comprising IFN-α and a cytoplasmic transduction peptide (CTP)
PCT/KR2009/001575 WO2010110503A1 (ko) 2009-03-27 2009-03-27 인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 IFN-α 융합 단백질

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2009/001575 WO2010110503A1 (ko) 2009-03-27 2009-03-27 인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 IFN-α 융합 단백질

Publications (1)

Publication Number Publication Date
WO2010110503A1 true WO2010110503A1 (ko) 2010-09-30

Family

ID=42781186

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/001575 WO2010110503A1 (ko) 2009-03-27 2009-03-27 인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 IFN-α 융합 단백질

Country Status (4)

Country Link
US (1) US8623348B2 (ko)
EP (1) EP2412730B1 (ko)
JP (1) JP5576928B2 (ko)
WO (1) WO2010110503A1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015526084A (ja) * 2012-08-13 2015-09-10 ジェイダブリュ クレアジェン インコーポレーテッド 細胞質残留性細胞膜透過ペプチド及びポリエチレングリコールが結合されたインターフェロン−α融合タンパク質

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas
US20200165312A1 (en) * 2017-06-28 2020-05-28 Lg Household & Health Care Ltd. Cosmetic composition for improving skin conditions comprising fusion protein including skin penetration enhancing peptide

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4695623A (en) 1982-05-06 1987-09-22 Amgen Consensus human leukocyte interferon
US20050019306A1 (en) * 2001-10-05 2005-01-27 Horvath Curt M. Hybrid fusion protein transcription regulator to induce interferon target gene expression
KR100608558B1 (ko) 2002-03-29 2006-08-03 크레아젠 주식회사 세포질 잔류성 세포막 투과 펩타이드 및 이의 용도
WO2009019456A1 (en) * 2007-08-08 2009-02-12 Asterion Limited Interferon fusion proteins

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6319691B1 (en) * 1999-06-15 2001-11-20 Usa Universe Bioengineering, Inc. Fusion proteins comprising IFN-alpha2b and TM-alpha1
PE20010490A1 (es) * 1999-08-13 2001-04-27 Hoffmann La Roche Micofenolato mofetil en asociacion con peg-ifn-alfa
EP1562634B1 (en) * 2002-11-15 2006-08-23 F. Hoffmann-La Roche Ag Positional isomers of pegylated interferon alpha 2a
PL376673A1 (pl) * 2003-02-18 2006-01-09 Merck Patent Gmbh Białka fuzyjne mutein interferonu alfa o ulepszonych właściwościach
WO2006029078A2 (en) * 2004-09-07 2006-03-16 The Regents Of The University Of California Targeting transducible molecules to specific cell types
RU2008109649A (ru) * 2005-08-15 2009-09-27 Ф.Хоффманн-Ля Рош Аг (Ch) ПЭГ-IFNα И РИБАВИРИН ДЛЯ ЛЕЧЕНИЯ ВИРУСА ГЕПАТИТА В
EP2063905B1 (en) * 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
JP2010508271A (ja) * 2006-10-27 2010-03-18 ウェイ‐チャン シェン 脂質化インターフェロンおよびその使用
KR100900742B1 (ko) * 2007-05-17 2009-06-08 크레아젠 주식회사 인간 간암 동물모델 및 이를 이용한 수지상세포-유래 간암면역치료제의 예방 및 치료 효능을 분석하는 방법

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4695623A (en) 1982-05-06 1987-09-22 Amgen Consensus human leukocyte interferon
US4897471A (en) 1982-05-06 1990-01-30 Amgen Consensus human leukocyte interferon
US20050019306A1 (en) * 2001-10-05 2005-01-27 Horvath Curt M. Hybrid fusion protein transcription regulator to induce interferon target gene expression
KR100608558B1 (ko) 2002-03-29 2006-08-03 크레아젠 주식회사 세포질 잔류성 세포막 투과 펩타이드 및 이의 용도
US7101844B2 (en) 2002-03-29 2006-09-05 Creagene, Inc. Cytoplasmic transduction peptides and uses thereof
JP4188909B2 (ja) 2002-03-29 2008-12-03 クレアゼン インコーポレーテッド 細胞質残留性細胞膜透過ペプチド及びこれの用途｛ＣｙｔｏｐｌａｓｍｉｃＴｒａｎｓｄｕｃｔｉｏｎＰｅｐｔｉｄｅｓａｎｄＵｓｅｓｔｈｅｒｅｏｆ｝
WO2009019456A1 (en) * 2007-08-08 2009-02-12 Asterion Limited Interferon fusion proteins

Non-Patent Citations (28)

* Cited by examiner, † Cited by third party
Title
"Pharmaceutical Dosage Forms", 1980, MARCEL DECKER
"Remington's Pharmaceutical Sciences", 1995
BJORN F. LILLEMEIER ET AL.: "STAT1 from the cell membrane to the DNA.", THE EMBO JOURNAL, vol. 20, no. 10, 2001, pages 2508 - 2517, XP008153267 *
CAPECCHI, M.R., CELL, vol. 22, 1980, pages 479
COHEN, S.N. ET AL., PROC. NATL. ACAC. SCI. USA, vol. 9, 1973, pages 2110 - 2114
DAEYOU KIM ET AL.: "Cytoplasmic transduction peptide (CTP): New approach for the delivery of biomolecules into cytoplasm in vitro and in vivo.", EXPERIMENTAL CELL RESEARCH., vol. 312, no. 8, 2006, pages 1277 - 1288, XP024945021 *
DOWER, W.J. ET AL., NUCLEIC. ACIDS RES., vol. 16, 1988, pages 6127 - 6145
FRANCESCO M.: "Peptide and protein PEGylation: a review of problems and solutions", VERONESE BIOMATERIALS, vol. 22, 2001, pages 405 - 417
GOPAL, MOL. CELL BIOL., vol. 5, 1985, pages 1188 - 1190
GRAHAM, F.L. ET AL., VIROLOGY, vol. 52, 1973, pages 456
HANAHAN, D., J. MOL. BIOL., vol. 166, 1983, pages 557 - 580
HERSKOWITZ, I., HAGEN, D., ANN. REV. GENET., vol. 14, 1980, pages 399 - 445
HOOVER, JOHN E.: "Remington's Pharmaceutical Sciences", 1975, MACK PUBLISHING CO.
I.G. IVANOV, N. MARKOVA ET AL.: "Constitutive expression of native human interferon-a gene in E. coli", INT. J. BIOCHEM., vol. 21, 1989, pages 983 - 985, XP025195529, DOI: doi:10.1016/0020-711X(89)90230-9
I.G. IVANOV, R. ALEXANDROVA, B. DRAGULEV ET AL.: "Effect of tandemly repeated AGG triplets on the translation of CAT-mRNA in E. coli", FEBS LETT., vol. 307, 1992, pages 173 - 176
KWAN SIK LEE, DONG JOON KIM ET AL.: "Management of Chronic Hepatitis B", THE KOREAN JOURNAL OF HEPATOLOGY, vol. 13, 2007, pages 447 - 488
M. ROBINSON, R. LILLEY, S. LITTLE ET AL.: "Codon usage can affect efficiency of translation of genes in Escherichia coli", NUCLEIC ACIDS RES., vol. 12, 1984, pages 6663 - 671
M.J. ROBERTS, M.D. BENTLEY ET AL.: "Chemistry for peptide and protein PEGylation", ADVANCED DRUG DELIVERY REVIEWS, vol. 54, 2002, pages 459 - 476, XP002354432, DOI: doi:10.1016/S0169-409X(02)00022-4
NEUMANN, E. ET AL., EMBO J., vol. 1, 1982, pages 841
R. ALEXANDROVA, M. EWEIDA ET AL.: "Domains in human interferon-alpha 1 gene containing tandems of arginine codons AGG play the role of translational initiators in E coli", INT. J. BIOCHEM. CELL BIOL., vol. 27, 1995, pages 469 - 473
R.M. HORTON, Z. CAI ET AL.: "Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction", BIOTECHNIQUES, vol. 8, 1990, pages 528 - 535
SAMBROOK ET AL.: "Molecular Cloning, A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS
SCHEIT: "Nucleotide Analogs", 1980, JOHN WILEY
SEONYOUNG YANG ET AL.: "Modification of Interferon- alpha with Cytoplasmic Transduction Peptide.", KOREAN SOCIETY FOR BIOTECHNOLOGY AND BIOENGINEERING 2008 SPRING MEETING ABSTRACT INFORMATION, 18 April 2008 (2008-04-18), pages 136, XP009171299 *
UHLMAN, PEYMAN, CHEMICAL REVIEWS, vol. 90, 1990, pages 543 - 584
WONG, T.K. ET AL., GENE, vol. 10, 1980, pages 87
YANG ET AL., PROC. NATL. ACAD. SCI., vol. 87, 1990, pages 9568 - 9572
YANOFSKY, C., J. BACTERIOL., vol. 158, 1984, pages 1018 - 1024

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015526084A (ja) * 2012-08-13 2015-09-10 ジェイダブリュ クレアジェン インコーポレーテッド 細胞質残留性細胞膜透過ペプチド及びポリエチレングリコールが結合されたインターフェロン−α融合タンパク質

Also Published As

Publication number Publication date
EP2412730B1 (en) 2014-09-10
EP2412730A4 (en) 2012-08-22
US8623348B2 (en) 2014-01-07
US20120134961A1 (en) 2012-05-31
JP2012521754A (ja) 2012-09-20
EP2412730A1 (en) 2012-02-01
JP5576928B2 (ja) 2014-08-20

Similar Documents

Publication Publication Date Title
WO2009147248A3 (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
WO2010043650A3 (en) Amino acid sequences targeting human cd4, cxcr4, ccr5, tlr4, alphav integrin, beta3- integrin, betal -integrin, human alpha2- integrin, cd81, sr-bi, claudin-i, claudin-6 and claudin-9, respectively, and neutralizing viral entry
IL195611A0 (en) Pharmaceutical composition for the treatment of viral infections and/or tumor diseases by inhibiting protein folding and protein breakdown
IL212184A (en) Conditional expression vector of protein (s) acting as immunomodulator (s), engineered training cells, their pharmaceutical composition and their use in drug preparation
WO2009053339A3 (en) Cholesterol derivatives of inhibitors of viral fusion
MX351069B (es) Proteinas de union abcma (cd269/tnfrsf17).
UA115027C2 (uk) Cxcr2-зв'язуючі поліпептиди
JP2013107899A5 (ko)
EA201200515A1 (ru) Полипептиды и их применение
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
WO2007131238A3 (en) Compounds and methods for modulating expression apob
WO2012083302A3 (en) Compositions and methods for the treatment or prevention of human adenovirus-36 infection
WO2012093931A8 (en) Antimicrobial fusion compounds and uses thereof
WO2012159052A3 (en) Targeted delivery of proteins across the blood brain barrier
WO2012007839A3 (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
WO2010047830A3 (en) Agents for hcv treatment
WO2007126363A8 (en) Antisecretory protein for use in the treatment of compartment syndrome
WO2009020559A3 (en) Agents that inhibit p-tefb interactions and methods of use thereof
WO2009046464A8 (en) Articular cartilage gene therapy with recombinant vector encoding bmp-7
WO2010110503A1 (ko) 인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 IFN-α 융합 단백질
WO2006137938A3 (en) Antibody fragments for protection from pathogen infection and methods of use thereof
WO2010041241A3 (en) Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding
Alfaleh et al. David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors
WO2013033319A3 (en) A cluster of neutralizing antibodies to hepatitis c virus
WO2010107742A3 (en) Methods and compositions of treating a flaviviridae family viral infection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09842353

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012501917

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2009842353

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13260490

Country of ref document: US